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John A. Bittl, MD“Every man’s island.every man’s watchman, is
his conscience.”
—Harper Lee, Go Set a Watchman: A Novel (1)
“For thus hath the Lord said unto me, Go, set a
watchman, let him declare what he seeth.”
—Book of Isaiah 21:6 (2)T he recent approval of the WATCHMAN device(Boston Scientiﬁc, Natick, Massachusetts)by the U.S. Food and Drug Administration
(FDA) is a milestone for the subspecialty of structural
cardiology. The WATCHMAN device is indicated for
patients with nonvalvular atrial ﬁbrillation (NVAF)
who are at increased risk of stroke and are suitable
for anticoagulation with warfarin, but for whom there
is a reasonable rationale to undergo nonpharmacolog-
ical alternative therapy (3).
Closing the left atrial appendage (LAA) in patients
with NVAF to prevent stroke makes mechanistic
sense. In a classic surgical series of patients with
NVAF, 91% of left atrial thrombi were found to be
anchored in or conﬁned to the LAA (4). Indirect
evidence suggests that warfarin eliminates thrombi
from the LAA (5), and strong evidence shows that
adjusted-dose warfarin reduces stroke by about 60%
in NVAF (6), thus deﬁning 1 of the most successful
treatments in cardiovascular medicine.
Because warfarin causes bleeding and needs con-
stant monitoring, the search for nonpharmacological
approaches to exclude the LAA has been intense.
Investigation of the WATCHMAN device began in the
PROTECT AF (Prospective Randomized Evaluation
of the Watchman LAA Closure Device In Patients
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paper to disclose.Therapy) trial (7), which met its noninferiority
hypothesis but showed higher rates of the safety
outcomes of major bleeding, pericardial effusion, and
device embolization with WATCHMAN than with
chronic warfarin (relative risk [RR]: 1.69; Bayesian
credible interval: 1.01 to 3.19). To address the safety
issue, further investigation was undertaken in the
PREVAIL (Prospective Randomized Evaluation of the
Watchman LAA Closure Device In Patients With Atrial
Fibrillation Versus Long Term Warfarin Therapy) trial
(8), which failed to demonstrate noninferiority of the
WATCHMAN device compared with warfarin for the
initial coprimary endpoint, but succeeded in satis-
fying the primary safety goal. The FDA’s Circulatory
System Devices Panel reviewed the WATCHMAN data
on 3 occasions and ultimately recommended approval
on October 14, 2014, on the basis of a split vote of 6 to
5 that favored the beneﬁts of WATCHMAN over its
risks for reducing thromboembolism in high-risk pa-
tients with NVAF (9).
A subsequent meta-analysis (10) showed that use of
the WATCHMAN device caused fewer hemorrhagic
strokes (0.15 events vs. 0.96 events/100 patient-years
[PY]; hazard ratio [HR]: 0.22; p ¼ 0.004) but more
ischemic strokes (1.6 events vs. 0.9 events/100 PY; HR:
1.95; p ¼ 0.005) than did chronic warfarin therapy.
Exploratory analyses found that the use of the
WATCHMANwas associatedwith fewer cardiovascular
deaths (1.1 events vs. 2.3 events/100 PY; HR: 0.48; 95%
conﬁdence interval [CI]: 0.28 to 0.81; p ¼ 0.006) but
not with lower all-cause mortality (HR: 0.73; 95% CI:
0.52 to 1.00; p¼0.07). Post-hoc analyses that excluded
periprocedural complications found that the use of the
WATCHMAN was associated with fewer hemorrhagic
events between 7 days and 2.7 years after randomiza-
tion than was long-term warfarin (0.2 events vs. 1.0
events/100 PY; HR: 0.22; p ¼ 0.004).
In this issue of JACC: Cardiovascular Interventions,
Price et al. (11) present more details about bleeding
with the WATCHMAN device from a pooled, patient-
level analysis of the PROTECT AF (7) and PREVAIL
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1934(8) trials. The investigators found that the overall rate
of major bleeding was no different after WATCHMAN
implantation or long-term warfarin during 3.1 years of
follow-up (3.5 events vs. 3.6 events/100 PY; RR: 0.96;
95% CI: 0.66 to 1.39; p ¼ 0.97). Post-hoc analyses
excluding periprocedural events found that LAA
closure was associated with reduced bleedingSEE PAGE 1925between 7 days and 3.1 years of follow-up (1.8 events
vs. 3.6 events/100 PY; RR: 0.49; 95% CI: 0.32 to 0.75;
p ¼ 0.002). Subgroup analyses that excluded peri-
procedural events and identiﬁed patients who were
able to stop all anticoagulant and antiplatelet therapy
found again that LAA closure was associated with
reduced bleeding between 6 months and 3.1 years
after randomization compared with long-term
warfarin (1.0 events vs. 3.5 events/100 PY; RR: 0.28;
95% CI: 0.16 to 0.49; p < 0.001).
The primary bleeding outcomes in the current report
(11) are disconcerting, given that the rationale for using
WATCHMAN implantation in place of long-term
warfarin is to reduce bleeding, and the post-hoc sub-
group comparisons that eliminate periprocedural
bleeding from the comparisons should be viewed
as biased to favor use of the WATCHMAN device.
Despite concerns about the secondary analyses,
the WATCHMAN investigational program (7,8,10,11)
nevertheless constitutes the best evidence for a non-
pharmacological alternative to long-term warfarin to
prevent stroke in NVAF. No other device for LAA
closure has been studied as rigorously. The Amplatzer
Cardiac Plug (St. JudeMedical, St. Paul, Minnesota) hasbeen used outside of the United States under the CE
(Conformité Européenne) mark, despite little evidence
to support its use (3). The Lariat (SentreHeart, Redwood
City, California), which is also CE marked and has
received FDA approval as a method of soft tissue
approximation but not stroke prevention, is being used
off-label in clinical practice for LAA occlusion (3).
Recent reports of deaths and adverse events on the
FDA’s Mechanical and User Facility Device Experience
Database (12) suggest that there should be amoratorium
on the use of Lariat or restriction to a compassionate-
use basis until evidence of safety is produced.
Lest some readers view this editorial comment as a
feuilleton—a ﬁrst-person ﬁlleting of a topic—I will
dispel that notion and conclude that the WATCHMAN
device has successfully undergone scientiﬁc and
regulatory scrutiny, ﬁlls an important clinical need,
and despite concerns about how bleeding was
analyzed in well-executed clinical trials, should be
considered on a selective basis for high-risk patients
with NVAF who cannot tolerate long-term warfarin
therapy. Before LAA closure becomes a regular
consideration for patients with NVAF who wish to
avoid taking warfarin, more observation is required
in a literal, biblical, and rigorously scientiﬁc sense
to determine whether WATCHMAN implantation
compared with long-term warfarin actually lowers
the risk of bleeding in patients with NVAF.
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